1. COVID-19 as a Trigger of Recurrent Guillain–Barré Syndrome
- Author
-
Erin P. McDonnell, Martin J. Blaser, Ram C. Gowda, Yesha H. Parekh, Nicole J. Altomare, Payal Parikh, and Mark H. Lazar
- Subjects
0301 basic medicine ,Microbiology (medical) ,Nosology ,Pediatrics ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,SARS-CoV-2 neurological complications ,demyelinating polyradiculopathies ,Coronavirus disease 2019 (COVID-19) ,lcsh:Medicine ,Chronic inflammatory demyelinating polyneuropathy ,Case Report ,medicine.disease_cause ,Viral infection ,03 medical and health sciences ,para-infectious Guillain–Barré syndrome ,0302 clinical medicine ,Chronic Inflammatory Demyelinating Neuropathy ,medicine ,Immunology and Allergy ,Molecular Biology ,Coronavirus ,General Immunology and Microbiology ,Guillain-Barre syndrome ,business.industry ,lcsh:R ,Polyradiculopathies ,medicine.disease ,030104 developmental biology ,Infectious Diseases ,recurrent Guillain–Barré syndrome ,business ,030217 neurology & neurosurgery - Abstract
Coronavirus 2019 (COVID-19) has been reported to trigger Guillain–Barré syndrome (GBS). While uncommon, recurrent GBS (rGBS) episodes, triggered by antecedent viral infections, have been reported in a small proportion of GBS patients, here we describe a patient with a recurrent case of GBS, occurring secondary to COVID-19 infection. Before this patient’s episode, he had two prior GBS flares, each precipitated by a viral infection followed by complete recovery besides intermittent paresthesias. We also consider the nosology of this illness in the spectrum of rGBS and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with their differing natural histories, prognosis, and therapeutic approaches. For patients who have a history of inflammatory demyelinating polyradiculopathies who develop COVID-19, we recommend close observation for neurologic symptoms over the next days and weeks.
- Published
- 2020